Trial Profile
A Phase IB/II Study of Second Line Therapy With Panitumumab, Irinotecan and Everolimus (PIE) in Metastatic Colorectal Cancer With KRAS WT
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Irinotecan (Primary) ; Panitumumab (Primary)
- Indications Carcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms PIE
- 08 May 2018 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 02 Nov 2017 Status changed from active, no longer recruiting to completed.
- 21 Jan 2017 Results (n=33) of biomarker substudy, presented at the 2017 Gastrointestinal Cancers Symposium